Eledon Pharmaceuticals, Inc. (ELDN) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 11.79M USD | Liabilities, Current |
| Cash and equivalents | 6.80M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $11.79M | $6.80M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $13.46M | $6.15M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $18.34M | $22.81M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $14.30M | $3.67M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $13.72M | $5.74M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $9.19M | $8.50M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $11.58M | $20.55M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $12.49M | $6.75M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $6.03M | $26.04M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $4.25M | $5.66M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $3.90M | $4.61M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $2.90M | $3.67M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $4.90M | $40.95M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $5.48M | $46.48M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $6.47M | $56.41M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $6.28M | $65.89M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $3.28M | $70.46M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $2.96M | $76.68M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $4.40M | $84.83M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $4.05M | $94.04M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $2.68M | $101.13M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $4.21M | $108.58M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $2.48M | $114.19M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $6.13M | $114.46M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $1.10M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $1.88M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $1.32M | $8.79M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $1.66M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $1.95M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $3.24M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | $12.97M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $17.23M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $2.31M | $19.09M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $3.16M | $22.50M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $2.42M | $24.40M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $2.82M | $23.22M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $6.34M | $18.63M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $7.82M | $12.16M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $6.18M | $14.30M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $6.16M | $24.02M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $5.66M | $33.17M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $4.65M | $59.08M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $5.75M | $94.16M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $4.24M | $105.26M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $5.37M | $105.46M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $21.15M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $27.01M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $2.21M | $31.75M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $23.11M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $11.69M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $2.25M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |